605 research outputs found
Recommended from our members
Cooperative smartphone relay selection based on fair power utilization for network coverage extension
This paper presents a relay selection algorithm based on fair battery power utilization for extending mobile network coverage and capacity by using a cooperative communication strategy where mobile devices can be utilized as relays. Cooperation improves the network performance for mobile terminals, either by providing access to out-of-range devices or by facilitating multi-path network access to connected devices. In this work, we assume that all mobile devices can benefit from using other mobile devices as relays and investigate the fairness of relay selection algorithms. We point out that signal strength based relay selection inevitably leads to unfair relay selection and devise a new algorithm that is based on fair utilization of power resources on mobile devices. We call this algorithm Credit based Fair Relay Selection (CF-RS) and in this paper show through simulation that the algorithm results in fair battery power utilization, while providing similar data rates compared with traditional approaches. We then extend the solution to demonstrate that adding incentives for relay operation adds clear value for mobile devices in the case they require relay service. Typically, mobile devices represent self-interested users who are reluctant to cooperate with other network users, mainly due to the cost in terms of power and network capacity. In this paper, we present an incentive based solution which provides clear mutual benefit for mobile devices and demonstrate this benefit in the simulation of symmetric and asymmetric network topologies. The CF-RS algorithm achieves the same performance in terms of achievable data rate, Jain's fairness index and utility of end devices in both symmetric and asymmetric network configurations
Recommended from our members
Patient privacy protection using anonymous access control techniques
Objective: The objective of this study is to develop a solution to preserve security and privacy in a healthcare environment where health-sensitive information will be accessed by many parties and stored in various distributed databases. The solution should maintain anonymous medical records and it should be able to link anonymous medical information in distributed databases into a single patient medical record with the patient identity. Methods: In this paper we present a protocol that can be used to authenticate and authorize patients to healthcare services without providing the patient identification. Healthcare service can identify the patient using separate temporary identities in each identification session and medical records are linked to these temporary identities. Temporary identities can be used to enable record linkage and reverse track real patient identity in critical medical situations. Results: The proposed protocol provides main security and privacy services such as user anonymity, message privacy, message confidentiality, user authentication, user authorization and message replay attacks. The medical environment validates the patient at the healthcare service as a real and registered patient for the medical services. Using the proposed protocol, the patient anonymous medical records at different healthcare services can be linked into one single report and it is possible to securely reverse track anonymous patient into the real identity. Conclusion: The protocol protects the patient privacy with a secure anonymous authentication to healthcare services and medical record registries according to the European and the UK legislations, where the patient real identity is not disclosed with the distributed patient medical records
Dynamic bandwidth allocation in multi-class IP networks using utility functions.
PhDAbstact not availableFujitsu Telecommunications Europe Lt
Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy.
Anti-MAG demyelinating neuropathy is difficult to treat. All immunotherapies have failed except for rituximab, a chimeric B-cellâdepleting monoclonal antibody against CD20, that helps up to 40% of patients based on 2 controlled and several uncontrolled series.1,â,3 Because the majority of these patients are left disabled, stronger antiâB-cell agents might be promising.
We describe clinical response and autoantibody changes after treatment with obinutuzumab (Gazyva), a new generation of humanized anti-CD20 monoclonal antibodies, in 2 patients with anti-MAG neuropathy who continued to worsen despite multiple courses of rituximab. Obinutuzumab, approved for chronic lymphocytic leukemia (CLL), exerts greater peripheral and lymphoid B-cell depletion4 and might be more effective in rituximab-refractory patients. © Rakocevic et al
Propriedades fisiolĂłgicas e estruturais de braquiĂĄria (Brachyaria bryzantha Hochst. ex A. Rich) em consĂłrcio com eucalipto (Eucalyptus citriodora Hook.) em um sistema silvipastoril no noroeste do ParanĂĄ.
1 CD-ROM
- âŠ